supp.fit

Uridine: study protocols

6 study groups say how much Uridine participants took a day. These are the doses the studies gave. They are not a recommendation.

Uridine: what the research found →

Dose per serving from research

6 study groups in 5 studies say how much Uridine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 33% of 6 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
0
50 mg to 100 mg
0
100 mg to 250 mg
1
250 mg to 500 mg
1
500 mg to 1 g
2
1 g to 2.5 g
0
2.5 g to 5 g
0
5 g to 10 g
0
10 g to 25 g
0
25 g to 50 g
0
50 g to 100 g
0
over 100 g
1

Commonly used together

4 of 6 study groups took Uridine with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Vitamin B12
4

6 study groups

Study
Preliminary effects of oral uridine on the ocular surface in dry eye patients
2009 · oral uridine group · Patients aged 13–76 years with moderate-to-severe bilateral dry eye syndrome; mean age 55 years
150 mg90 days15
Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial
2007 · uridine group · patients with HIV-associated lipoatrophy receiving unchanged HAART
108 g90 days—
[Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study]
1996 · Nucleus CMP forte · Adults aged 25–79 with idiopathic or HTLV-1-associated progressive spastic paraparesis
9 mg26 weeks22
Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients
2024 · experimental treatment group · Adults aged 18–85 of both sexes with painful radiculopathy of any etiology, upper neuropathic pain, and pain VAS ≥60 mm
300 mg8 weeks63
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication.
625 mg24 weeks501
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2.
625 mg24 weeks201